TMPO

Across TCGA pan-cancer cohorts, TMPO mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMPO data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TMPO mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMPO expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where TMPO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.873	0.600	.002	41	view →
LUAD	DFS	Median	III,IV	0.728	0.283	.006	13	view →
CCRCC	DFS	Median	II,III,IV	0.817	0.984	.029	8	view →
PDAC	OS	Quartile	All	0.677	0.418	.019	6	view →
OV	DFS	Tertile	All	0.793	1.000	.034	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMPO–LSCC (DFS)

Open the LSCC breakdown →